Reversing dopaminergic sensitization

Mov Disord. 2017 Dec;32(12):1679-1683. doi: 10.1002/mds.27213. Epub 2017 Nov 18.

Authors

Anna Castrioto^{1

2

3}, Sebastien Carnicella^{1

2}, Valérie Fraix^{1

2

3}, Stéphan Chabardes^{1

2

4}, Elena Moro^{1

2

3}, Paul Krack⁵

Affiliations

¹ Université Grenoble Alpes, Grenoble Institut des Neurosciences (GIN), Grenoble, France.
² Centre hospitalier universitaire de Grenoble, Inserm, U1216, F-38000, Grenoble, France.
³ Movement Disorders Unit, Neurology Department, CHU de Grenoble, Grenoble, France.
⁴ Neurosurgery Unit, Centre hospitalier universitaire de Grenoble, Grenoble, France.
⁵ Department of Clinical Neurosciences (Neurology), University Hospital of Geneva, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

PMID: 29150871
DOI: 10.1002/mds.27213

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antiparkinson Agents / adverse effects*
Humans
Levodopa / adverse effects*
Parkinson Disease / drug therapy*

Substances

Antiparkinson Agents
Levodopa